Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1B STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS

Trial Profile

A PHASE 1B STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Utomilumab (Primary)
  • Indications Colon cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Thymoma; Thyroid cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE-0036
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 23 Feb 2017 Planned number of patients changed from 23 to 45.
    • 23 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top